Skip to main navigation

Skip to content

Pharmaceutical Programs

Pharmaceutical

Rare Cannabinoid Manufacturing

Manufacturing

IR Nav

Investor

About

Corporate

Learn

Learn

Menu

Pharmaceutical Programs

Pharmaceutical

Rare Cannabinoid Manufacturing

Manufacturing

IR Nav

Investor

About

Corporate

Learn

Learn

Financials & AGM Materials

Financials & AGM Materials

Show all

2023

Q1

Quarterly Press Release 109.8 KB
10-Q

2022

AGM Materials

Form of Proxy - for Registered Shareholders 94 KB
Notice and Access Notification - Internet Availability 229.4 KB
Notice of Meeting and Information Circular 544.8 KB
Notice of Meeting 429.7 KB

Q4

Quarterly Press Release 130.3 KB
10-K

Q3

Quarterly Press Release 129.7 KB
10-Q

Q2

Quarterly Press Release 104.8 KB
10-Q

Q1

Quarterly Press Release 236.3 KB
10-Q

2021

AGM Materials

2021 Annual Report 2 MB
Form of Proxy - for Registered Shareholders 70.9 KB
Notice and Access Notification - Internet Availability 166.4 KB
Notice of Meeting and Information Circular 355.5 KB
Notice of Meeting 77 KB
Voting Instruction Form - for non-Registered Shareholders 70.8 KB

Q4

Quarterly Press Release 237 KB
10-K 1.8 MB

Q3

Quarterly Press Release 91 KB
10-Q 350.1 KB

Q2

Quarterly Press Release 254.9 KB
10-Q 392.4 KB

Q1

10-Q 768.9 KB

2020

AGM Materials

Amended Notice of AGM and Information (Proxy) Circular 842.4 KB
Form of Proxy 70 KB

Q4

Quarterly Press Release 288 KB
Financial Statements 303.8 KB
MD&A 302.6 KB
Annual Information Form 2.1 MB

Q3

Quarterly Press Release 288.9 KB
Financial Statements 303.2 KB
MD&A 257.4 KB

Q2

Quarterly Press Release 264.4 KB
Financial Statements 286.5 KB
MD&A 272.2 KB

Q1

Quarterly Press Release 99.7 KB
Financial Statements 300.6 KB
MD&A 277.5 KB

2019

AGM Materials

Notice of AGM and Information (Proxy) Circular 701.6 KB
Form of Proxy 70.2 KB

Q4

Quarterly Press Release 134.9 KB
Financial Statements 684.3 KB
MD&A 241.6 KB
Annual Information Form 1.2 MB

Q3

Quarterly Press Release 168.4 KB
Financial Statements 263.8 KB
MD&A 221.9 KB

Q2

Quarterly Press Release 173 KB
Financial Statements 255.4 KB
MD&A 225.3 KB

Q1

Quarterly Press Release 168.5 KB
Financial Statements 263.2 KB
MD&A 220.1 KB

2018

AGM Materials

Notice of AGM and Information (Proxy) Circular 508.4 KB
Form of Proxy 69.5 KB

Q4

Quarterly Press Release 167.1 KB
Financial Statements 693.2 KB
MD&A 247.9 KB
Annual Information Form 1 MB

Q3

Quarterly Press Release 143.3 KB
Financial Statements 390.4 KB
MD&A 209.4 KB

Q2

Financial Statements 390.6 KB
MD&A 205.5 KB

Q1

Financial Statements 374.6 KB
MD&A 212.1 KB

2017

Q4

Financial Statements 556.5 KB
MD&A 234.7 KB
Annual Information Form 1.6 MB
Letter from the President and Chief Executive Officer 67.4 KB

Q3

Financial Statements 405.5 KB
MD&A 211 KB

Q2

Financial Statements 412.6 KB
MD&A 213.4 KB

Q1

Financial Statements 490.4 KB
MD&A 256.9 KB

Investor Alerts

Sign up for investor alerts!

Information Request

Send us a request for information

#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical Programs

Pharmaceutical

Cannabinoids in Development
INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
Neurodegenerative Disease
Novel Cannabinoid Analogs

Rare Cannabinoid Manufacturing

Manufacturing

Cannabinoid Manufacturing Expertise
IntegraSyn™ - Cannabinoid Manufacturing
Baymedica Cannabinoid Biosynthesis
Rare Cannabinoid Ingredients

IR Nav

Investor

News Releases
Events
Stock Information
Corporate Governance
Financials & AGM
Filings
Presentations
Media

About

Corporate

Management
Board of Directors
Scientific Advisory Board
Partners and Collaborators
Events Calendar
Careers
Contact

Learn

Learn

What is Cannabinol (CBN)?
What is Epidermolysis Bullosa (EB)?
What is Glaucoma?
Cannabinoid Manufacturing Economics 101
GMP Manufacturing Standards by Product Type
Cannabis Treatments for Glaucoma
Cannabinoid Science
Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

Legal Nav

Privacy Policy
Terms of Use
Legal Disclaimer

Social icons

Find Us On:
>
>
>